Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab and trastuzumab (phesgo) in combination with paclitaxel and carboplatin for reimbursement as a treatment option for the treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.
This is written in the approval document as:
Neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.
Citation
Pertuzumab and Trastuzumab (Phesgo), PACLitaxel and CARBOplatin Therapy (TRAIN-2), 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/790-pertuzumab-trastuzumab-phesgo-paclitaxel-and-carboplatin-therapy-train-2-.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab |